BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26333940)

  • 1. Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.
    Thaden JT; Keller AE; Shire NJ; Camara MM; Otterson L; Huband M; Guenther CM; Zhao W; Warrener P; Stover CK; Fowler VG; DiGiandomenico A
    J Infect Dis; 2016 Feb; 213(4):640-8. PubMed ID: 26333940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates.
    Tabor DE; Oganesyan V; Keller AE; Yu L; McLaughlin RE; Song E; Warrener P; Rosenthal K; Esser M; Qi Y; Ruzin A; Stover CK; DiGiandomenico A
    J Infect Dis; 2018 Nov; 218(12):1983-1994. PubMed ID: 30016475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.
    Yasumoto H; Katoh H; Kinoshita M; Shimizu M; Hamaoka S; Akiyama K; Naito Y; Sawa T
    Microbiol Immunol; 2016 Feb; 60(2):114-20. PubMed ID: 26696420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T; Ito E; Nguyen VH; Haight M
    Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.
    DiGiandomenico A; Keller AE; Gao C; Rainey GJ; Warrener P; Camara MM; Bonnell J; Fleming R; Bezabeh B; Dimasi N; Sellman BR; Hilliard J; Guenther CM; Datta V; Zhao W; Gao C; Yu XQ; Suzich JA; Stover CK
    Sci Transl Med; 2014 Nov; 6(262):262ra155. PubMed ID: 25391481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
    Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature.
    Thanabalasuriar A; Surewaard BG; Willson ME; Neupane AS; Stover CK; Warrener P; Wilson G; Keller AE; Sellman BR; DiGiandomenico A; Kubes P
    J Clin Invest; 2017 Jun; 127(6):2249-2261. PubMed ID: 28463232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model.
    Le HN; Quetz JS; Tran VG; Le VTM; Aguiar-Alves F; Pinheiro MG; Cheng L; Yu L; Sellman BR; Stover CK; DiGiandomenico A; Diep BA
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483116
    [No Abstract]   [Full Text] [Related]  

  • 9. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults.
    Ali SO; Yu XQ; Robbie GJ; Wu Y; Shoemaker K; Yu L; DiGiandomenico A; Keller AE; Anude C; Hernandez-Illas M; Bellamy T; Falloon J; Dubovsky F; Jafri HS
    Clin Microbiol Infect; 2019 May; 25(5):629.e1-629.e6. PubMed ID: 30107283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
    Imamura Y; Yanagihara K; Fukuda Y; Kaneko Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Sawa T; Wiener-Kronish JP; Kohno S
    Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of
    Long MB; Gilmour A; Kehl M; Tabor DE; Keller AE; Warrener P; Gopalakrishnan V; Rosengren S; Crichton ML; McIntosh E; Giam YH; Keir HR; Brailsford W; Hughes R; Belvisi MG; Sellman BR; DiGiandomenico A; Chalmers JD
    Am J Respir Crit Care Med; 2024 Jul; 210(1):35-46. PubMed ID: 38754132
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
    Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
    Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.
    Shime N; Sawa T; Fujimoto J; Faure K; Allmond LR; Karaca T; Swanson BL; Spack EG; Wiener-Kronish JP
    J Immunol; 2001 Nov; 167(10):5880-6. PubMed ID: 11698464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PcrV titers in non-cystic fibrosis patients with Pseudomonas aeruginosa respiratory tract infection.
    Nagaoka K; Yamashita Y; Kimura H; Kimura H; Suzuki M; Fukumoto T; Hayasaka K; Yoshida M; Hara T; Maki H; Ohkawa T; Konno S
    Int J Infect Dis; 2019 Oct; 87():54-59. PubMed ID: 31419482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
    Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa.
    Golpasha ID; Mousavi SF; Owlia P; Siadat SD; Irani S
    Bosn J Basic Med Sci; 2015 May; 15(2):15-24. PubMed ID: 26042508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models.
    Le HN; Tran VG; Vu TTT; Gras E; Le VTM; Pinheiro MG; Aguiar-Alves F; Schneider-Smith E; Carter HC; Sellman BR; Stover CK; DiGiandomenico A; Diep BA
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160288
    [No Abstract]   [Full Text] [Related]  

  • 19. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
    Wang Q; Li H; Zhou J; Zhong M; Zhu D; Feng N; Liu F; Bai C; Song Y
    Respir Physiol Neurobiol; 2014 Mar; 193():21-8. PubMed ID: 24418353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy.
    Lynch SV; Flanagan JL; Sawa T; Fang A; Baek MS; Rubio-Mills A; Ajayi T; Yanagihara K; Hirakata Y; Kohno S; Misset B; Nguyen JC; Wiener-Kronish JP
    Microb Pathog; 2010 Jun; 48(6):197-204. PubMed ID: 20211240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.